Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determination of Minimal Residual Disease by Deep ctDNA Sequencing.

NCT07660627 is registered in ClinicalTrials.gov with Masaryk Memorial Cancer Institute as lead sponsor.

NCT NCT07660627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07660627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determination of Minimal Residual Disease by Deep ctDNA Sequencing.
Lead sponsor
Masaryk Memorial Cancer Institute
Phase
Not applicable
Overall status
Recruiting
Start date
August 22, 2022
Completion date
December 31, 2026
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, gastric cancer, pancreatic cancer